84315-25-3

Usage

Uses

5,7-Difluoro-1-indanone is used as pharmaceutical intermediate.

InChI:InChI=1/C9H6F2O/c10-6-3-5-1-2-8(12)9(5)7(11)4-6/h3-4H,1-2H2

Upstream product

• 95333-92-9 3-(3,5-difluorophenyl)propionyl chloride 
• 84315-23-1 3,5-difluorocinnamic acid 
• 461-96-1 3,5-difluorobromobenzene 
• 32085-88-4 3,5-difluorobenzaldehyde 
• 923977-12-2 5-(3,5-difluoro-benzyl)-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 84315-24-2 3-(3,5-difluorophenyl)propionic acid 

Downstream Products

• 1595028-22-0 8-(4-methoxyphenyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-20-8 8-(3-fluorophenyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-18-4 8-(4-fluorophenyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-16-2 8-phenyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-14-0 8-benzyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 
• 1595028-04-8 8-cyclohexyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)-3,4-dihydroisoquinolin-1(2H)-one 

Relevant academic research and scientific papers

Synthetic method of 7-fluoro-5-hydroxy-2,3-dihydro-1hydrogen-indene-1-one

The invention relates to a synthetic method of 7-fluoro-5-hydroxy-2,3-dihydro-1hydrogen-indene-1-one. The technical problem that there is no synthetic method suitable for industrialization at present is mainly solved. The synthetic method of the invention

SPIRO BENZIMIDAZOLE DERIVATIVES AS ACID PUMP INHIBITORS

This invention relates to compounds of the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, R5, R6, R7, R8 and A are each as described herein or a pharmaceutically acceptable salt, and compositions containing such c

Efficient synthesis of halo indanones via chlorosulfonic acid mediated Friedel-Crafts cyclization of aryl propionic acids and their use in alkylation reactions

Several halo indanones were synthesized from benzyl Meldrum's acid derivatives in two steps. Although several Lewis acids are effective for the Friedel-Crafts ring-closing reaction on more electron-rich arenes, in the case of the electron-deficient arenes this chemistry is not efficient. Here it is reported that chlorosulfonic acid (used as solvent) is an efficient reagent for cyclization of electron-withdrawing arenes. These molecules are potentially useful for subsequent alkylation reactions. The selective alkylation of 5,7-dibromo indanone is demonstrated using Pd-catalyzed Grignard coupling to provide monoalkylated indanone in good yield.

4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same

The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha2B adrenergic receptors in preference over alpha2A and alpha2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.

Indanylidenes. 1. Design and synthesis of (E)-2-(4,6-difluoro-1-indanylidene)acetamide, a potent, centrally acting muscle relaxant with antiinflammatory and analgesic activity

The design of rigid cyclic analogues derived from cinnamamide 1, (E)-N-cyclopropyl-3-(3-fluorophenyl)prop-2-enamide, and β-methylcinnamamide 2, (E)-N-cyclopropyl-3-(3-fluorophenyl)but-2-enamide, has led to the discovery of the potent, centrally acting muscle relaxant (E)-2-(4,6-difluoro-1-indanylidene)acetamide, 17. Compound 17 also possesses potent antiinflammatory and analgesic activity. This paper describes the synthesis and the muscle relaxant, antiinflammatory, and analgesic structure-activity relationships of 17 and 67 of its analogues. Compound 17 has been taken into phase I clinical trials.

Epoxidation with Dioxiranes derived from 2-Fluoro-2-substituted-1-tetralones and -1-indanones

Homochiral 2-fluoro-2-substituted-1-tetralones (10a, 10b, 13) and ethyl 2-fluoro-1-indanone-2-carboxylate (16) have been isolated.The dioxirane derivatives of these ketones have been prepared in situ, and have been shown to epoxidise alkenes but not enantioselectively.The dioxirane derivative of methyl 2,5,7-trifluoro-1-indanone-2-carboxylate (18) has been shown to be comparatively efficient in epoxidation.

Cannabis. Part 25. Synthesis of Cannabispirenone-B and its 5,7-Difluoro-analogue

The naturally occuring cannabispirenone-B (1a) was synthesized by spiroannelation of the piperidine anamine of 5,7-dimethoxyindan-1-carbaldehyde to O-methylcannabispirenone (1b), followed by selective demethylation with lithium iodide in 2,4,6-collidine.I